These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 8042835)
1. Acyclovir and ganciclovir in cytomegalovirus. Moss GB Ann Intern Med; 1994 Sep; 121(5):385. PubMed ID: 8042835 [No Abstract] [Full Text] [Related]
2. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients. Winston DJ; Busuttil RW Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129 [TBL] [Abstract][Full Text] [Related]
3. Elimination of cytomegalovirus disease in liver transplant patients treated prophylactically with combination cytomegalovirus hyperimmune globulin and ganciclovir. Prian GW; Koep LJ Transplant Proc; 1994 Oct; 26(5 Suppl 1):54-5. PubMed ID: 7940977 [No Abstract] [Full Text] [Related]
4. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children. Green M; Kaufmann M; Wilson J; Reyes J Clin Infect Dis; 1997 Dec; 25(6):1344-9. PubMed ID: 9431375 [TBL] [Abstract][Full Text] [Related]
5. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Winston DJ; Wirin D; Shaked A; Busuttil RW Lancet; 1995 Jul; 346(8967):69-74. PubMed ID: 7603215 [TBL] [Abstract][Full Text] [Related]
6. Ganciclovir/acyclovir prophylaxis reduces the incidence of cytomegalovirus infections in pancreas transplant recipients. Harland RC; Vernon WB; Bunzendahl H; Thompson JK; Lawrence C; Bollinger RR Transplant Proc; 1994 Apr; 26(2):432-3. PubMed ID: 8171488 [No Abstract] [Full Text] [Related]
10. Cytomegalovirus prophylaxis by ganciclovir followed by high-dose acyclovir in renal transplantation: a randomized, controlled trial. Pouteil-Noble C; Megas F; Chapuis F; Bosshard S; Colin C; Hadj-Aissa A; Pozet N; Martin X; Lefrançois N; Garnier JL; Aymard M; Touraine JL Transplant Proc; 1996 Oct; 28(5):2811. PubMed ID: 8908072 [No Abstract] [Full Text] [Related]
11. Viral prophylaxis in hepatic transplantation: preliminary report of a randomized trial of acyclovir and gancyclovir. Nakazato PZ; Burns W; Moore P; Garcia-Kennedy R; Cox K; Esquivel C Transplant Proc; 1993 Apr; 25(2):1935-7. PubMed ID: 7682357 [No Abstract] [Full Text] [Related]
12. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021 [TBL] [Abstract][Full Text] [Related]
13. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation. Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289 [TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of prophylaxis of CMV disease in solid organ transplantation: is Ganciclovir a superior agent to Acyclovir? Gourishankar S; Wong W; Dorval M Transplant Proc; 2001; 33(1-2):1870-2. PubMed ID: 11267547 [No Abstract] [Full Text] [Related]
15. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial. Singh N; Yu VL; Mieles L; Wagener MM; Miner RC; Gayowski T Ann Intern Med; 1994 Mar; 120(5):375-81. PubMed ID: 8304654 [TBL] [Abstract][Full Text] [Related]
16. Effect of high-dose acyclovir on survival in allogeneic marrow transplant recipients who received ganciclovir at engraftment or for cytomegalovirus pp65 antigenemia. Boeckh M; Gooley TA; Bowden RA J Infect Dis; 1998 Oct; 178(4):1153-7. PubMed ID: 9806049 [TBL] [Abstract][Full Text] [Related]
17. Why valganciclovir should not be indicated for liver recipients and high-dose acyclovir should not be removed from international cytomegalovirus guidelines. Kalil AC; Florescu DF Transplantation; 2011 Jan; 91(1):e8-9; author reply e10. PubMed ID: 21441850 [No Abstract] [Full Text] [Related]
18. Randomized trial of ganciclovir followed by high-dose oral acyclovir vs ganciclovir alone in the prevention of cytomegalovirus disease in pediatric liver transplant recipients: preliminary analysis. Green M; Reyes J; Nour B; Beatty D; Kaufman M; Wilson J; Todo S; Tzakis A Transplant Proc; 1994 Feb; 26(1):173-4. PubMed ID: 8108926 [No Abstract] [Full Text] [Related]
19. Preemptive therapy for cytomegalovirus with oral ganciclovir after liver transplantation. Singh N Transplantation; 2002 Jun; 73(12):1977; author reply 1977-8. PubMed ID: 12131704 [No Abstract] [Full Text] [Related]
20. Randomized trial of pre-emptive or prophylactic valganciclovir therapy for prevention of cytomegalovirus infection in renal transplantation. Santos RD; Brennan DC J Am Soc Nephrol; 2012 Sep; 23(9):1446-8. PubMed ID: 22878958 [No Abstract] [Full Text] [Related] [Next] [New Search]